19:37 , Dec 6, 2016 |  BC Innovations  |  Distillery Therapeutics

Dermatology

INDICATION: Dermatitis Mouse studies suggest inhibiting signaling between IL-33 and IL1RL1 could help treat poison ivy-induced allergic dermatitis. A mouse model of poison ivy-induced dermatitis had high levels of IL-33 in the skin. In the model,...
08:00 , Feb 8, 2016 |  BioCentury  |  Product Development

Asthma armament

Amgen Inc.'s AMG 282 could allow Genentech Inc. to treat an asthma patient population not currently covered by its existing pipeline - or by any other targeted therapies in the clinic. The mAb has a...
08:00 , Feb 1, 2016 |  BC Week In Review  |  Company News

Amgen, Roche, Genentech deal

Amgen granted Roche’s Genentech unit exclusive, worldwide rights to develop and commercialize AMG 282, an antibody that inhibits the binding of IL-33 ( NF-HEV) to IL-1 receptor-like 1 ( IL1RL1; ST2). Genentech plans...
02:29 , Jan 29, 2016 |  BC Extra  |  Company News

Genentech in-licenses Amgen's AMG 282

The Genentech Inc. unit of Roche (SIX:ROG; OTCQX:RHHBY) received exclusive global rights from Amgen Inc. (NASDAQ:AMGN) to AMG 282, an antibody against IL-1 receptor-like 1 ( IL1RL1; ST2). The antibody prevents IL-33 from binding to...